Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

p53 isoforms can regulate p53 transcriptional activity.

Jean-Christophe Bourdon1, Kenneth Fernandes, Fiona Murray-Zmijewski

  • 1Department of Surgery, Cancer Research-UK Cell Transformation Research Group, University of Dundee, Ninewells Hospital, Scotland, UK. j.bourdon@dundee.ac.uk

Genes & Development
|September 1, 2005
PubMed
Summary

The p53 gene, like its relatives p73 and p63, has an alternative promoter and produces multiple splice variants. These p53 variants are expressed differently in normal tissues and human breast tumors, impacting cancer biology.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

NEDD8, stress granules, and amyotrophic lateral sclerosis: unveiling the therapeutic potential of the NEDP1 protease.

Essays in biochemistry·2025
Same author

Pharmacological activation of p53 induces dose-dependent changes in endothelial cell fate during angiogenic sprouting.

Cell death & disease·2025
Same author

Confirmation by conformation: rescue of mutant p53 in AML.

Blood·2025
Same author

NEDD8-specific protease 1 deficiency as a novel driver of hepatoblastoma development through dysregulation of the CAND1-NEDD8 pathway.

Hepatology (Baltimore, Md.)·2025
Same author

Deneddylation of ribosomal proteins promotes synergy between MLN4924 and chemotherapy to elicit complete therapeutic responses.

Cell reports·2025
Same author

Editor's Note: The MDM2/MDMX-p53 Antagonist PM2 Radiosensitizes Wild-Type p53 Tumors.

Cancer research·2025

Area of Science:

  • Molecular Biology
  • Genetics
  • Cancer Research

Background:

  • The p53-related genes, p73 and p63, are known to express multiple splice variants and N-terminally truncated forms from an alternative promoter.
  • Previously, no alternative promoter or multiple splice variants had been described for the p53 gene.

Purpose of the Study:

  • To investigate if the p53 gene shares a similar structure with p73 and p63, including the presence of an alternative promoter and multiple splice variants.
  • To explore the expression patterns and functional significance of p53 variants in normal tissues and human breast tumors.

Main Methods:

  • Gene structure analysis of the human p53 gene.
  • Splice variant identification and characterization.
  • Tissue-specific expression analysis of p53 variants in normal human tissues.

Related Experiment Videos

  • Comparative analysis of p53 variant expression in normal breast tissue versus human breast tumors.
  • Functional assays to assess the promoter binding and transcriptional activity of p53beta and the dominant-negative effect of Delta133p53.

    • Main Results:

    • The human p53 gene possesses an alternative promoter and transcribes multiple splice variants, similar to p73 and p63.
    • p53 variants exhibit tissue-dependent expression in normal human tissues.
    • The alternative promoter in the p53 gene family is evolutionarily conserved from Drosophila to humans.
    • Differential expression of p53 variants was observed in human breast tumors compared to normal breast tissue.
    • p53beta demonstrates differential promoter binding and enhances target gene expression, while Delta133p53 acts as a dominant-negative inhibitor of p53-mediated apoptosis.

    Conclusions:

    • The p53 gene structure, including an alternative promoter and splice variants, is conserved across the p53 family, suggesting a crucial role in their diverse functions.
    • The differential expression of p53 isoforms in tumors may contribute to the observed difficulties in correlating p53 status with cancer biology and drug sensitivity.